Table.
1 | CryαA: | F: 5′-gagattcacggcaaacacaa-3′ |
R: 5′-aaattcacgggaaatgtagcc-3′ | ||
2 | CryαB: | F: 5′-cctgagccccttctaccttc-3′ |
R: 5′-tccttctccaaacgcatctc-3′ | ||
3 | Cryγs: | F: 5′-gaataccagcgttggatgg-3′ |
R: 5′-gaaggacagtcttccgtgg-3′ | ||
4 | Vim: | F: 5′-ccaaccttttcttccctgaa-3′ |
R: 5′-tgagtgggtgtcaaccagag-3′ | ||
5 | Fgf7: | F: 5′-cagacagcagacacggaac-3′ |
R: 5′-gcctcctcctatttgtgaac-3′ | ||
6 | EGFP: | F: 5′-cttcttcaagtccgccat-3′ |
R: 5′-caccttgatgccgttcttct-3′ | ||
7 | Hsf4: | F: 5′-gagccacagtcagcagcac-3′ |
R: 5′-cgctcccctcatctagca-3′ | ||
8 | Gapdh: | F: 5′-ggtgaaggtcggtgttgaacg-3′ |
R: 5′-ctcgctcctggaagatggtg-3′ | ||
9 | Hsp25: | F: 5′-ggaagtctgaacagtctgga-3′ |
R: 5′-gtatcaaaagagcgcacag-3′ | ||
10 | Hsp70: | F: 5′-cagtagcctgggaagacata-3′ |
R: 5′-tagtacacagtgccaagacg-3′ | ||
11 | Hsp60: | F: 5′-cagagttcctcagaagttgg-3′ |
R: 5′-catccagtaaggcagttctc-3′ | ||
12 | Bfsp1: | F: 5′-acagacaagaatgggttacg-3′ |
R: 5′-aggtatgatcacaggacagg-3′ | ||
13 | Bfsp2: | F: 5′-ggctttctgtcaagaagcta-3′ |
R: 5′-ctcaaggacatcatccagac-3′ | ||
14 | LP82: | F: 5′-acacagaccaggaaagtgag-3′ |
R: 5′-tgtgttgaggacattcttga-3′ | ||
15 | Calp2: | F: 5′-attctggatgtccttcagtg-3′ |
R: 5′-ttggtgagtttccacttctt-3′ | ||
16 | Dlad: | F: 5′-gacagcaaagcctctaagaa-3′ |
R: 5′-gtccacagcttcaccatatt-3′ |
Approximately 1 μg of total RNA was treated by DNase I (Invitrogen) and reverse transcribed by using Superscript III (Invitrogen) in 20 μl. For RT-qPCR, 1 μL of cDNA was amplified with a SYBR Green Master mix for 45 cycles (Hoffmann-La Roche, Basel, Switzerland) and analyzed as described.37 Primers used for RT-qPCR (Figs. 7B, 7C, 8A, 8B) are shown above. F, forward; R, reverse.